User:Jodolphsson/Mikael Hedeland

Carl Mikael Hedeland (born July 7, 1973) is a chemist and professor of Analytical Pharmaceutical Chemistry at the Department of Medicinal Chemistry at Uppsala University in Sweden. His expertise is in mass spectrometry, chromatography, bioanalysis, drug metabolism and doping control.

Biografi
Hedeland completed his basic education at Uppsala University, where he obtained a Master in Pharmaceutical Science (MSc) in 1997. In 1999 he obtained a Ph.D. in Analytical Pharmaceutical Chemistry at Uppsala University. Following the doctorate he was employed at Swedish Veterinary Agency (SVA) between 1999 and 2018. During these years he specialized in drug metabolism and doping control. While at SVA he was appointed: Associate Professor(Docent) (2007), Visiting Professor (2013) and Adjunct Professor (2015). All of these at Uppsala University.

In 2018 he were appointed full chair Professor of Analytical Pharmaceutical Chemistry at Uppsala University.

Research
Hedeland's research mainly consists of drugs in the environment, drug metabolism, doping control and metabolomics. This he conducts with the research group Analytisk Farmaceutisk Kemi (AFK) at Uppsala university.

Medicines in the environment
AFK studies and develops methods for making ecotoxicological assessments and for identifying what is formed naturally and what is affected when pharmaceutical substances are transformed in different aquatic systems. This research has been noticed by e.g. the Swedish national public television broadcaster and Sweden's national publicly funded radio broadcaster.

Drug metabolism and doping control
AFK studies how the body takes up drugs classified as doping and develops methods to be able to detect these drugs. They also focus on potential doping substances that can be obtained via the internet that aren't classified as pharmaceuticals.

Metabolomics
AFK develops methods to be able to determine samples at the molecular level. They apply this to obtain prognostics and diagnostics for various forms of cancer. In 2023, the Swedish Research Council recognized Hedeland's project.